

Review Article**Role of Coenzyme Q10 in Aging, Oxidative Stress, Cancer & Critically Ill Patients**Almas Zahid¹, Halima Usman²¹Shifa International Hospital Islamabad, Pakistan.²Shifa College of Pharmaceutical Sciences, Shifa Tameer-e-Millat University, Islamabad, Pakistan*Correspondence: halima.scps@stmu.edu.pk

© The Author(s) 2024. This article is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

Abstract

Aging is a slow process of physiological changes that lead to a decline in the biological activities of organisms. Stopping or reversing this process has been the subject of extensive research for centuries. In aging, mitochondria, which are ubiquitously present in the cells and tissues of the body, play a seminal role. There has been a close association between the optimum function of mitochondria and aging. Coenzyme Q10 (CoQ10), a well-known, integral cofactor of the electron transport chain in the mitochondria of human cells, is a powerful antioxidant and a free radical scavenger. With advancing age, a significant reduction occurs in natural levels of CoQ10. A low level of CoQ10 is found to compromise mitochondrial activity, increase oxidative stress, and lead to clinically heterogeneous diseases, including cancers. Supplementation with CoQ10 is believed to augment mitochondrial activity, confer antioxidant protection to cells and tissues, and retard the onset of various disorders. These observations lead the researchers to explore the anti-aging potential of CoQ10 and its utility in dietary therapies to counteract the negative impact of aging and boost longevity. In this review, we compiled, reviewed, and discussed various age-related pathologies in the context of CoQ10 deficiency and the effect of CoQ10 supplementation on improving these conditions.

Keywords: Coenzyme Q10, cancer, aging, oxidative stress, mitochondria**1. Introduction**

Coenzyme Q or ubiquinone occurs naturally in the hydrophobic region of the phospholipid bilayer of all biological membranes (Varela-López et al. 2016). It can also be produced synthetically, making it accessible for cases where deficiency is suspected. Endogenous CoQ 10 enzyme is an integral component of the mitochondrial electron transport chain, a vital player in intracellular metabolism, and an essential antioxidant (Hidalgo-Gutiérrez et al. 2021). At least 14 proteins are required to synthesize CoQ10 in mammalian cells. The initial step of this pathway involves the formation of a 4-hydroxybenzoic acid (4-HB) head and the hydrophobic polyisoprenoid tail.

The amino acid phenylalanine or tyrosine serves as the precursor of 4-HB formation. Subsequently, the addition of isopentenyl diphosphate molecules (obtained through the mevalonate pathway) catalyzed by the enzyme polyprenyl diphosphate synthase forms geranylgeranyl diphosphate or farnesyl diphosphate, which subsequently yields the polyisoprenoid tail (Shukla and Dubey 2018). PDSS1 and PDSS2 work together as a heterodimer to accelerate the reaction that combines isoprene units, which are the building blocks of polyisoprenoid tail. Enzymes encoded by *COQ2*, *COQ3*, *COQ5*, *COQ6*, and *COQ7* are also implicated in multiple biochemical reactions during CoQ10 synthesis. For instance,

the conjugation of benzoquinone to the side chain is catalyzed by the enzyme transcribed from *COQ2*, which is located in the inner membrane of the mitochondria (Doimo et al. 2014).


Additionally, the enzymes encoded by the remaining genes mentioned above modify the benzoquinone ring of CoQ10 via methylation, decarboxylation, and hydroxylation (Kawamukai 2016). *COQ9* has been reported to attach itself to various biosynthetic intermediates of CoQ10, such as demethoxyubiquinone (DMQ), a *COQ7* substrate, through physical interaction with *COQ7* itself (García-Corzo et al. 2012, Lohman et al. 2014). Researchers have also found that *ADCK1*, *ADCK2*, *ADCK5*, and *PTC7p* proteins have displayed the ability to influence the rate at which CoQ10 is formed (Kawamukai 2016). While the complete process of CoQ10 biosynthesis is still ambiguous, incomplete information regarding extra mitochondrial biosynthesis is also reported. *UBIAD1* is a non-mitochondrial prenyltransferase that contains a UbiA prenyltransferase domain, a homolog of the mitochondrial enzyme *CoQ2*. *UBIAD1* is found in the Golgi apparatus (Mugoni et al. 2013). And has been reported to support the biosynthesis of CoQ10 in this organelle (Mugoni et al. 2013).

Plasma levels of CoQ₁₀ range between 0.40 and 1.91 μmol/L (0.34–1.65 μg/mL) in normal individuals (Barcelos and Haas 2019). Different articles state different concentrations of CoQ10 in different organs. For instance, in the lungs, the level is 8 μg/g, and 114 μg/g in the heart. General recommendations for CoQ10 supplementation in healthy elderly individuals typically range from 30 to 200 mg daily. Some studies suggest higher doses of up to 1,200 mg/day may be beneficial for specific health concerns (Hathcock and Shao 2006).

2. Genetic Mutations in CoQ10 Pathway & Diseases

CoQ10 deficiency is categorized into two types: primary and secondary. The primary category arises from genetic mutations in the CoQ10 synthesis pathway, whereas secondary deficiencies are caused by certain diseases or their medications. Mutations in genes involved in the biosynthesis of CoQ10 form the basis of mitochondrial diseases and may be associated with clinically heterogeneous pathologies. The five significant phenotypes of primary CoQ10 deficiency identified so far are (1) infantile multisystem form, (2) isolated myopathy, characterized by muscle weakness, myoglobinuria, exercise intolerance, and elevated creatine kinase (CK) (Kaeberlein et al. 2005) (3) encephalomyopathy (recurrent myoglobinuria, encephalopathy, and mitochondrial myopathy), (4) cerebellar ataxia (cerebellar atrophy associated with other neurologic manifestations and, occasionally, endocrine dysfunctions, and (5) nephropathy. (Figure 1). Some patients have also exhibited retinopathy, optic atrophy, sensorineural hearing loss, and hypertrophic cardiomyopathy (Alcázar-Fabra, Trevisson, and Brea-Calvo 2018). Moreover, individuals harboring mutations in the serine/threonine-protein kinase *B-raf* gene or *BRAF* are found to exhibit cardiofaciocutaneous (CFC) syndrome, while mutations in the electron-transferring flavoprotein dehydrogenase gene (*ETFDH*) are held responsible for isolated myopathy. Similarly, mutations in the aprataxin- *APTX*-gene, which present as oculomotor apraxia and ataxia, are also attributed to CoQ10 deficiency (Desbats et al. 2015). Single nucleotide substitutions, deletions, and duplications in mitochondrial DNA (mtDNA) display associations with CoQ10 deficiency (Desbats et al. 2015). Relations between secondary CoQ10 deficiency in mouse models and mitochondrial

Figure 1 Genetic mutations in the CoQ10 pathway result in diseases.



diseases have also been observed (Kühl et al. 2017) particularly in models associated with resistance to insulin and adipose and muscle tissue (Fazakerley et al. 2018). The wide range of clinical presentations related to CoQ10 deficiencies is attributed to its unique structural features, characteristics, and different metabolic functions.


3. CoQ10 and the Ageing Skin

Continuous exposure to environmental stress has a significant impact on the physiological behavior of the cutaneous cells of our skin and the skin as an entire organ. As the skin cells age, various factors such as ultraviolet (UV) radiation and, more importantly, intrinsic as well as extrinsic reactive oxygen species (ROS) contribute to an increased accumulation of ROS inside the cells. This excessive buildup of ROS ultimately leads to impaired mitochondrial functioning and cellular damage (Ames, Shigenaga, and Hagen 1993). Consequently, the cell adapts to this damage by shifting to anaerobic glycolysis as a compensatory

mechanism (McKenzie et al. 2007, von Kleist-Retzow et al. 2007).

CoQ10 is classically known to be an essential component of the electron transport chain in the mitochondria. Therefore, it is reasonable to infer that the provision of CoQ10 can improve energy metabolism in cells. As the age increases, the antioxidant capacity of cells weakens, and exposure to UV radiation further depletes CoQ10 reserves in skin cells and augments the intracellular concentration of ROS (Hoppe et al. 1999). As mentioned earlier, loss of mitochondrial function due to old age may promote non-mitochondrial compensatory pathways, e.g., glycolysis. This inference is corroborated by reports indicating increased glucose uptake and elevated lactate production in aged fibroblasts *in vitro* (Poot et al. 1987, Zwerschke et al. 2003). Compared to the other dermal layers, CoQ10 concentration is ten times greater in the epidermis (Shindo et al. 1994). The epidermis, the outermost skin layer, is exposed to the most significant environmental stressors and UV radiation, which diminishes CoQ10 in

Figure 2. Schematic representation of reversible effects of synthetically derived CoQ10 in aging skin.




the skin, among the other antioxidants (Podda et al. 1998).

A randomized, controlled study was conducted on 73 healthy, non-smoking female volunteers aged 20-66 years. Participants applied two CoQ10 formulations (348 μ M and 870 μ M ubiquinone) twice daily for two weeks. The results showed that topically applied CoQ10 effectively penetrates the skin, undergoes metabolic transformation, and exhibits antioxidant properties, supporting cellular energy levels. This is particularly important for older individuals and for replenishing declining CoQ10 levels in the skin (Knott et al. 2015).

CoQ10 formulation, once applied, can provide great benefits to the keratinocytes found in the epidermal skin layer. Furthermore, after applying CoQ10 topical preparation for a short period, protective effects on mitochondrial function and improved mitochondrial activity have been observed *in vivo* even after exposure to UV radiation (Figure 2). Despite extensive

scientific research, the exact pathways that connect poor mitochondrial functioning and increased glycolytic flux with advanced age are yet to be established; however, it is believed that AMP-activated protein kinase (AMPK), which serves as a super metabolic regulator, is also a regulator of energy metabolism overall (Hardie, Salt, and Davies 2000). Studies show that suboptimal glucose utilization in epidermis keratinocytes is due to a shift to anaerobic glycolysis due to age-dependent mitochondrial dysfunction and subsequent loss of aerobic metabolic capacity (Sreedhar, Aguilera-Aguirre, and Singh 2020). Evidence highlights the positive anti-aging potential of CoQ10 as shown by the rapid pro-mitochondrial benefits seen post-application of a CoQ10 topical preparation; therefore, it hints at the potential use of CoQ10 formulations in anti-aging cosmeceuticals (Hseu et al. 2019).

Figure 3. Periodontal inflammation and the role of CoQ10.



4. CoQ10 and Oxidative Stress

It has been shown that oxidative stress plays a significant role in Cadmium (Cd)-mediated cytotoxicity (Ann et al. 2010, Ercal, Gurer-Orhan, and Aykin-Burns 2001). Due to the ability of CoQ10 to be reformed via reduction mechanisms inside cells, it confers protection to vital biomolecules such as DNA, proteins, and lipids from being subjected to oxidation (Crane 2001). CoQ10 has been observed to preserve the mitochondrial membrane by free radical ROS scavenging in oxidative stress models (Somayajulu et al. 2005, Song et al. 2017). Moreover, protection against Cd-stimulated oxidative damage has been observed in CoQ10 pretreated rats (Ognjanović et al. 2008). In patients suffering from a wide range of pathologies, such as cardiac diseases (hypertension and heart failure), as well as neurodegenerative disorders such as Parkinson's disease, CoQ10 provided a shield against oxidative stress (Fotino, Thompson-Paul, and Bazzano 2013, Rosenfeldt and Linden 2007, Seet et al. 2014, Spindler, Beal, and Henchcliffe 2009). Owing to its safety and fewer side effects, CoQ10 has become more frequent,

along with other antioxidants, in treating oxidative stress linked with Cd. Hepatoprotective effects of CoQ10 against statin-induced hepatotoxicity are also thought to be mediated through its antioxidant actions (Jahan et al. 2022). Vitamin C and vitamin E recycling and regeneration are just some of the many pathways by which CoQ10 augments the antioxidant defense mechanism of cells (Beyer 1994, Lass and Sohal 2000, Ognjanović et al. 2010).

In recent years the scientists have also explored the connection between CoQ10 and ferroptosis. Ferroptosis is a type of iron-dependent cell death marked by a large amount of iron accumulation and lipid peroxidation. Ferroptosis-inducing factors can directly or indirectly affect glutathione peroxidase through different pathways, resulting in a decrease in antioxidant capacity and accumulation of lipid reactive oxygen species (ROS) in cells, ultimately leading to oxidative cell death. (Qi et al. 2022). Doll et al. and Bersuker et al performed a study to identify Ferroptosis suppressors that can function independently of the key regulator glutathione peroxidase (Fikry et al. 2024). By

using a CRISPR Cas9 knockout screen, they identified gene apoptosis-inducing factor mitochondrial 2 (AIFM-2), which was later named ferroptosis suppressor protein 1 (FSP1). FSP-1 was found to effectively combat lethal lipid peroxidation in the absence of glutathione peroxidase. Moreover, it was found that myristoylated FSP anchored to the plasma membrane served as a crucial enzyme that reduced ubiquinone to ubiquinol, restoring the reduced pool of CoQ10. The reduced form of CoQ10 acts as a powerful antioxidant that suppresses lipid peroxidation through free radical scavenging (Doll et al. 2019).

5. Role of CoQ10 in Modulating Severity of Illness


Little research and seldom clinical studies have been conducted to investigate the effect of CoQ10 supplementation in severe illnesses. According to one study, patients critically ill with cardiovascular diseases and depleted CoQ10 exhibit a high risk of mortality (Shimizu et al. 2017). A randomized controlled study was performed on 38 critically ill sepsis patients. These individuals were divided into two groups. One group was given a placebo, whereas the other was administered ubiquinol (reduced form CoQ10) 400 mg daily for 7 days. Despite a significant elevation in CoQ10 levels, no significant benefit was seen in the test group compared to the placebo group regarding clinical patient or secondary outcomes such as mitochondrial damage, inflammation, and endothelial function (Donnino et al. 2011). However, it is important to consider that in sepsis patients who are critically ill, the clinical use of statins is quite frequent (Dobesh and Olsen 2014), and it is a well-established fact that statins can block CoQ10 synthesis, leading to the depletion of CoQ10 reserves inside cells (Okuyama et al. 2015).

6. CoQ10 and Selenium

Ubiquinone and Ubiquinol are the oxidized and reduced forms of CoQ10, respectively. For normal mitochondrial activity, which involves cellular respirations and antioxidant functions, the interconversion of CoQ10 into its oxidized and reduced forms should remain unhindered. CoQ10 is reduced to ubiquinol, through a two-step process involving electron and proton gain catalyzed by various oxidoreductases. This reduction enables CoQ10 to transfer two electrons, facilitating essential cellular functions like energy production and antioxidant activity. (Mantle, Dewsbury, and Hargreaves 2024). Thioredoxin reductase 1 (TrxR1), the most efficient enzyme responsible for the catalysis of ubiquinone reduction to Ubiquinol contains selenium in the form of selenocysteine, which is located in the active site of its structure (Zhong and Holmgren 2000). Therefore, it is reasonable to conclude that depletions in CoQ10 and selenium can negatively impact mitochondrial functioning by inhibiting the inter-conversion step. Selenocysteine, selenoprotein, and subsequent thioredoxin reductase synthesis can also be affected by changes in CoQ10 levels (Moosmann and Behl 2004). Consequently, selenium deficiencies can lead to reduced selenoproteins through inhibited CoQ10 production.

KISEL-10 (Pharma Nord ApS, based in Vejle, Denmark) is a supplement that contains CoQ10 and selenium in combination. A prospective, randomized, double-blind, placebo-controlled trial was conducted in Sweden (Linköping University and Karolinska University Hospital) to investigate the effects of selenium and coenzyme Q10 (CoQ10) supplementation (200 µg and 200mg per day) on cardiovascular health and mortality in elderly citizens. typically, doses range from 100-300 mg. C-reactive protein, copeptin, and adrenomedullin levels and other biomarkers of inflammation and oxidative

Figure 4 CoQ10 is also helpful for critically ill and cancer patients.



were found to have been significantly decreased in the supplemented group when compared to that of the placebo group (Alehagen et al. 2015, Alehagen, Aaseth, and Johansson 2015). Also, when compared to the placebo group, cardiovascular mortality dropped by 50% in the supplemented group (Alehagen et al. 2013). This study highlighted the potential of selenium and coenzyme Q10 supplementation in enhancing cardiovascular health and reducing mortality risks in elderly populations with low baseline levels of these nutrients. CoQ10 is typically administered orally, although a few clinical studies reported intravenous administration, whereas selenium can be given orally or intravenously (Okamura et al. 1984, Tsubaki et al. 1984).

7. CoQ10 and Periodontal Tissues

The anti-aging and antioxidant potential of CoQ10 has been demonstrated in various studies (Blatt and Littarru 2011, Temova Rakuša and Roškar 2021, Ayunin et al. 2022, Marcheggiani et al. 2021), which have shown its propensity to protect against oxidative stress and promote overall cellular health (Shetty, Forster, and Sumien 2013, Temova Rakuša and Roškar 2021). Based on this evidence, it is reasonable to conclude that CoQ10 can also mitigate age-linked inflammation in the periodontal tissues. Notably, numerous clinical studies have reported significant relief in chronic periodontitis after CoQ10 supplementation (Hanioka et al. 1994) (Ryo et al. 2011).

The application of CoQ10 on rat periodontal tissues has also revealed anti-aging effects. Deoxyguanosine (8-OGdG) levels increase in the serum with age, indicating oxidative stress (Yoneda et al. 2013). In 6-month-old rats, after treatment with topical CoQ10 preparation, a significant decline in 8-OHdG levels was observed. Furthermore, in the control group, the rats of the same age subjected to CoQ10 expressed lower 8-OHdG, also considered a biomarker for DNA damage via oxidation (Tomofuji et al. 2006). Thus, age-related oxidation and damage within the periodontal tissues can be reduced via CoQ10 as per the aforementioned results.

Additionally, concomitant administration of topical CoQ10 with conventional non-surgical treatment at the periodontal level exhibited marked improvement in chronic periodontitis as per a clinical investigation (Hanioka et al. 1994). Working as an endogenous antioxidant, CoQ10 levels increase in the gingivitis during inflammatory conditions to effectively combat progressive periodontitis (Prakash, Sunitha, and Hans 2010). Moreover, the anti-aging effect on normal periodontal tissues of CoQ10 has also been reported (Figure 3) (Yoneda et al. 2013).

8. CoQ10 and DNA Repair in Cancer Patients

A combination of CoQ10 (100mg Kaneka Corporation, Osaka, Japan), riboflavin (10mg Madras Pharmaceuticals, Chennai, India), and Niacin (50mg Madras Pharmaceuticals, Chennai, India) (CoRN) has been the subject of multiple scientific studies (Premkumar et al. 2008, Yuvaraj et al. 2009, Tippairote et al. 2022). In one such study, increased expression of the tumor suppressor gene *MnSOD* was observed after concomitant use of CoRN with the cytotoxic drug tamoxifen (Perumal, Shanthi, and Sachdanandam 2005c). Moreover, CoRN has been shown to restore both non-enzymatic and

enzymatic antioxidant systems, including lipid peroxide, to normal levels (Figure 4) (Perumal, Shanthi, and Sachdanandam 2005a). Enhancing the gluconeogenesis pathway to mitigate energy loss and subsequently protect against cancer cachexia is also an effect of this combination (Perumal, Shanthi, and Sachdanandam 2005b). Similarly, treatment with Tamoxifen reduced hyperlipidemia in breast cancer patients who used CoRN supplementation as their lipid levels returned to normal (Yuvaraj et al. 2007). Tumor marker levels of carcinoembryonic antigen have also been reduced (Premkumar et al. 2007a), along with a marked decrease in interleukins (IL-1b, IL-6, IL-8) and other cytokines such as vascular endothelial growth factor and TNF- α (Premkumar et al. 2007b). Ten Patients administered CoRN demonstrated a complete absence of Ras-association domain family 1, isoform A (RASSF1A) DNA methylation (Premkumar et al. 2008). RASSF1A DNA methylation is a convenient indicator of whether patients undergoing adjuvant tamoxifen treatment are responding well, as it aids in the timely detection of relapse (Fiegl et al. 2005). The lack of RASSF1A DNA methylation in the serum of these patients proved that CoRN could help prevent relapses in these patients.

9. Future Directions

Healthcare and treatment have steadily improved life expectancy over the past century. However, advanced age is accompanied by a persistent decline in physiological functions, which can lead to several debilitating diseases. Ageing is an inevitable complex physiological process governed by various factors. Several theories have been proposed to explain the process of aging. Damage resulting from oxidative stress is one of the most accepted theories implicating dysfunctional mitochondria as a significant contributor to aging. Many studies link CoQ10 deficiency to various clinical

mitochondrial diseases, a critical component of the mitochondrial electron transport pathway. The convincing data from these studies suggest that supplementation with CoQ10 may be a promising approach to preventing or mitigating mitochondrial damage.

Due to the free radical scavenging and the antioxidant propensity of CoQ10, it is widely used as a dietary supplement. A high concentration of CoQ10 is typically found in tissues with high energy demands, such as skeletal muscles and cardiac tissues (114 µg/g) (Gutierrez-Mariscal et al. 2021), and neurons. However, CoQ10 tissue concentration decreases with increased age and oxidative stress. As a result, numerous conditions have been linked to low levels of CoQ10, including cancer, fibromyalgia, muscular disorders, heart failures, neurodegenerative disease, and other age-related disorders. These observations accentuate its bioenergetic role and form the basis for CoQ10 clinical application and recommendation.

Despite promising results from various studies on CoQ10, extensive recommendations by medical practitioners, and wide availability over the counter, CoQ10 has not gained FDA approval to treat any medical condition. The clinical trials conducted to investigate CoQ10 efficacy yielded inconsistent outcomes. Multiple factors, such as lack of effectiveness, inadequate safety, problems related to patient recruitment, retention, and enrollment, insufficient funding to complete trials, and flawed study plans, might have contributed to the failure of clinical trials. Therefore, further studies and clinical trials with a good design based on a robust hypothesis involving a more significant number of participants undergoing treatment for long periods are needed to evaluate the safety, efficacy, and risk-benefit ratio of CoQ10.

Funding

It was a self-funded study. No intramural or extramural funding was obtained from any funding agency for this research project.

Conflicts of Interest

The authors of the study have no conflict of interest with this study.

Ethics Approval

NA

Consent to Participate

NA

Availability of Data

The data used in this manuscript is available from the corresponding author.

Author Contributions

Both authors contributed equally to this manuscript.

References

- Alcázar-Fabra, M., E. Trevisson, and G. Brea-Calvo. 2018. "Clinical syndromes associated with Coenzyme Q(10) deficiency." *Essays Biochem* no. 62 (3):377-398. doi: 10.1042/ebc20170107.
- Alehagen, Urban, Jan Aaseth, and Peter Johansson. 2015. "Reduced cardiovascular mortality 10 years after supplementation with selenium and coenzyme Q10 for four years: follow-up results of a prospective randomized double-blind placebo-controlled trial in elderly citizens." *PloS one* no. 10 (12):e0141641.
- Alehagen, Urban, Lina Benson, Magnus Edner, Ulf Dahlström, and Lars H Lund. 2015. "Association between use of statins and mortality in

- patients with heart failure and ejection fraction of $\geq 50\%$." *Circulation: Heart Failure* no. 8 (5):862-870.
- Alehagen, Urban, Peter Johansson, Mikael Björnstedt, Anders Rosén, and Ulf Dahlström. 2013. "Cardiovascular mortality and N-terminal-proBNP reduced after combined selenium and coenzyme Q10 supplementation: a 5-year prospective randomized double-blind placebo-controlled trial among elderly Swedish citizens." *International journal of cardiology* no. 167 (5):1860-1866.
- Ames, Bruce, M. K. Shigenaga, and Tory Hagen. 1993. "Ames BN, Shigenaga MK, Hagen TMOxidants, antioxidants, and the degenerative diseases of aging. Proc Natl Acad Sci USA 90:7915-7922." *Proceedings of the National Academy of Sciences of the United States of America* no. 90:7915-22. doi: 10.1073/pnas.90.17.7915.
- Ann, Cuypers, Plusquin Michelle, Remans Tony, Jozefczak Marijke, Keunen Els, Gielen Heidi, Opdenakker Kelly, Nair Ambily Ravindran, Munters Elke, and Artois Tom J. 2010. "Cadmium stress: an oxidative challenge." *Biometals* no. 23:927-940.
- Ayunin, Qurrota, Andang Miatmoko, Widji Soeratri, Tristiana Erawati, Joni Susanto, and Djoko Legowo. 2022. "Improving the anti-ageing activity of coenzyme Q10 through protransfersome-loaded emulgel." *Scientific Reports* no. 12 (1):906. doi: 10.1038/s41598-021-04708-4.
- Barcelos, I. P., and R. H. Haas. 2019. "CoQ10 and Aging." *Biology (Basel)* no. 8 (2). doi: 10.3390/biology8020028.
- Beyer, Robert E. 1994. "The relative essentiality of the antioxidative function of coenzyme Q—the interactive role of DT-diaphorase." *Molecular aspects of medicine* no. 15:s117-s129.
- Blatt, T., and G. P. Littarru. 2011. "Biochemical rationale and experimental data on the antiaging properties of CoQ(10) at skin level." *Biofactors* no. 37 (5):381-5. doi: 10.1002/biof.169.
- Crane, Frederick L. 2001. "Biochemical functions of coenzyme Q10." *Journal of the American College of Nutrition* no. 20 (6):591-598.
- Desbats, M. A., G. Lunardi, M. Doimo, E. Trevisson, and L. Salviati. 2015. "Genetic bases and clinical manifestations of coenzyme Q10 (CoQ 10) deficiency." *J Inherit Metab Dis* no. 38 (1):145-56. doi: 10.1007/s10545-014-9749-9.
- Dobesh, P. P., and K. M. Olsen. 2014. "Statins role in the prevention and treatment of sepsis." *Pharmacol Res* no. 88:31-40. doi: 10.1016/j.phrs.2014.04.010.
- Doimo, M., M. A. Desbats, C. Cerqua, M. Cassina, E. Trevisson, and L. Salviati. 2014. "Genetics of coenzyme q10 deficiency." *Mol Syndromol* no. 5 (3-4):156-62. doi: 10.1159/000362826.
- Doll, S., F. P. Freitas, R. Shah, M. Aldrovandi, M. C. da Silva, I. Ingold, A. Goya Grocin, T. N. Xavier da Silva, E. Panzilius, C. H. Scheel, A. Mourão, K. Buday, M. Sato, J. Wanninger, T. Vignane, V. Mohana, M. Rehberg, A. Flatley, A. Schepers, A. Kurz, D. White, M. Sauer, M. Sattler, E. W. Tate, W. Schmitz, A. Schulze, V. O'Donnell, B. Proneth, G. M. Popowicz, D. A. Pratt, J. P. F. Angeli, and M. Conrad. 2019. "FSP1 is a glutathione-independent ferroptosis

- suppressor." *Nature* no. 575 (7784):693-698. doi: 10.1038/s41586-019-1707-0.
- Donnino, M. W., M. N. Cocchi, J. D. Saliccioli, D. Kim, A. B. Naini, C. Buettner, and P. Akuthota. 2011. "Coenzyme Q10 levels are low and may be associated with the inflammatory cascade in septic shock." *Crit Care* no. 15 (4):R189. doi: 10.1186/cc10343.
- Ercal, Nuran, Hande Gurer-Orhan, and Nukhet Aykin-Burns. 2001. "Toxic metals and oxidative stress part I: mechanisms involved in metal-induced oxidative damage." *Current topics in medicinal chemistry* no. 1 (6):529-539.
- Fazakerley, D. J., R. Chaudhuri, P. Yang, G. J. Maghzal, K. C. Thomas, J. R. Krycer, S. J. Humphrey, B. L. Parker, K. H. Fisher-Wellman, C. C. Meoli, N. J. Hoffman, C. Diskin, J. G. Burchfield, M. J. Cowley, W. Kaplan, Z. Modrusan, G. Kolumam, J. Y. Yang, D. L. Chen, D. Samocha-Bonet, J. R. Greenfield, K. L. Hoehn, R. Stocker, and D. E. James. 2018. "Mitochondrial CoQ deficiency is a common driver of mitochondrial oxidants and insulin resistance." *Elife* no. 7. doi: 10.7554/eLife.32111.
- Fiegl, H., S. Millinger, E. Mueller-Holzner, C. Marth, C. Ensinger, A. Berger, H. Klocker, G. Goebel, and M. Widschwendter. 2005. "Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients." *Cancer Res* no. 65 (4):1141-5. doi: 10.1158/0008-5472.Can-04-2438.
- Fikry, H., L. A. Saleh, F. A. Mahmoud, S. A. Gawad, and H. A. Abd-Alkhalek. 2024. "CoQ10 targeted hippocampal ferroptosis in a status epilepticus rat model." *Cell Tissue Res* no. 396 (3):371-397. doi: 10.1007/s00441-024-03880-z.
- Fotino, A Domnica, Angela M Thompson-Paul, and Lydia A Bazzano. 2013. "Effect of coenzyme Q10 supplementation on heart failure: a meta-analysis." *The American journal of clinical nutrition* no. 97 (2):268-275.
- García-Corzo, Laura, Marta Luna-Sánchez, Carolina Doerrier, José A. García, Adela Guarás, Rebeca Acín-Pérez, Javier Bullejos-Peregrín, Ana López, Germaine Escames, José A. Enríquez, Darío Acuña-Castroviejo, and Luis C. López. 2012. "Dysfunctional Coq9 protein causes predominant encephalomyopathy associated with CoQ deficiency." *Human Molecular Genetics* no. 22 (6):1233-1248. doi: 10.1093/hmg/dd530.
- Gutierrez-Mariscal, Francisco M., Silvia de la Cruz-Ares, Jose D. Torres-Peña, Juan F. Alcalá-Diaz, Elena M. Yubero-Serrano, and José López-Miranda. 2021. "Coenzyme Q10 and Cardiovascular Diseases." *Antioxidants* no. 10 (6):906.
- Hanioka, T., M. Tanaka, M. Ojima, S. Shizukuishi, and K. Folkers. 1994. "Effect of topical application of coenzyme Q10 on adult periodontitis." *Mol Aspects Med* no. 15 Suppl:s241-8. doi: 10.1016/0098-2997(94)90034-5.
- Hathcock, John N., and Andrew Shao. 2006. "Risk assessment for coenzyme Q10 (Ubiquinone)." *Regulatory Toxicology and Pharmacology* no. 45 (3):282-288. doi: <https://doi.org/10.1016/j.yrtph.2006.05.006>.

- Hidalgo-Gutiérrez, A., P. González-García, M. E. Díaz-Casado, E. Barriocanal-Casado, S. López-Herrador, C. M. Quinzii, and L. C. López. 2021. "Metabolic Targets of Coenzyme Q10 in Mitochondria." *Antioxidants (Basel)* no. 10 (4). doi: 10.3390/antiox10040520.
- Hoppe, U, Jörg Bergemann, W Diembeck, Joachim Ennen, Sven Gohla, I Harris, J Jacob, J Kielholz, W Mei, and D Pollet. 1999. "Coenzyme Q₁₀, a cutaneous antioxidant and energizer." *Biofactors* no. 9 (2-4):371-378.
- Hseu, Y. C., Y. G. Ho, D. C. Mathew, H. R. Yen, X. Z. Chen, and H. L. Yang. 2019. "The in vitro and in vivo depigmenting activity of Coenzyme Q10 through the down-regulation of α -MSH signaling pathways and induction of Nrf2/ARE-mediated antioxidant genes in UVA-irradiated skin keratinocytes." *Biochem Pharmacol* no. 164:299-310. doi: 10.1016/j.bcp.2019.04.015.
- Jahan, Sarwat, Sher Afghan Khan, Abdus Salam, Inayat Ur Rehman, Omer Farooq, and Arsalan Afridi. 2022. "Comparative Analysis of the Hepatoprotective Potential of Coenzyme Q10 as a Preventive and a Therapeutic Agent in Statin-Induced Hepatotoxicity." *Molecular Medicine Communications* no. 2 (01):21-30.
- Kaeberlein, M., R. W. Powers, 3rd, K. K. Steffen, E. A. Westman, D. Hu, N. Dang, E. O. Kerr, K. T. Kirkland, S. Fields, and B. K. Kennedy. 2005. "Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients." *Science* no. 310 (5751):1193-6. doi: 10.1126/science.1115535.
- Kawamukai, M. 2016. "Biosynthesis of coenzyme Q in eukaryotes." *Biosci Biotechnol Biochem* no. 80 (1):23-33. doi: 10.1080/09168451.2015.1065172.
- Knott, A., V. Achterberg, C. Smuda, H. Mielke, G. Sperling, K. Dunkelmann, A. Vogelsang, A. Krüger, H. Schwengler, M. Behtash, S. Kristof, H. Diekmann, T. Eisenberg, A. Berroth, J. Hildebrand, R. Siegner, M. Winnefeld, F. Teuber, S. Fey, J. Möbius, D. Retzer, T. Burkhardt, J. Lüttke, and T. Blatt. 2015. "Topical treatment with coenzyme Q10-containing formulas improves skin's Q10 level and provides antioxidative effects." *Biofactors* no. 41 (6):383-90. doi: 10.1002/biof.1239.
- Kühl, Inge, Maria Miranda, Ilian Atanassov, Irina Kuznetsova, Yvonne Hinze, Arnaud Mourier, Aleksandra Filipovska, and Nils-Göran Larsson. 2017. "Transcriptomic and proteomic landscape of mitochondrial dysfunction reveals secondary coenzyme Q deficiency in mammals." *eLife* no. 6:e30952. doi: 10.7554/eLife.30952.
- Lass, Achim, and Rajindar S Sohal. 2000. "Effect of coenzyme Q10 and α -tocopherol content of mitochondria on the production of superoxide anion radicals." *The FASEB Journal* no. 14 (1):87-94.
- Lohman, D. C., F. Forouhar, E. T. Beebe, M. S. Stefely, C. E. Minogue, A. Ulbrich, J. A. Stefely, S. Sukumar, M. Luna-Sánchez, A. Jochem, S. Lew, J. Seetharaman, R. Xiao, H. Wang, M. S. Westphall, R. L. Wrobel, J. K. Everett,

- J. C. Mitchell, L. C. López, J. J. Coon, L. Tong, and D. J. Pagliarini. 2014. "Mitochondrial COQ9 is a lipid-binding protein that associates with COQ7 to enable coenzyme Q biosynthesis." *Proc Natl Acad Sci U S A* no. 111 (44):E4697-705. doi: 10.1073/pnas.1413128111.
- Mantle, D., M. Dewsbury, and I. P. Hargreaves. 2024. "The Ubiquinone-Ubiquinol Redox Cycle and Its Clinical Consequences: An Overview." *Int J Mol Sci* no. 25 (12). doi: 10.3390/ijms25126765.
- Marcheggiani, Fabio, Sebastian Kordes, Ilenia Cirilli, Patrick Orlando, Sonia Silvestri, Alexandra Vogelsang, Nadine Möller, Thomas Blatt, Julia M. Weise, Elisabetta Damiani, and Luca Tiano. 2021. "Anti-ageing effects of ubiquinone and ubiquinol in a senescence model of human dermal fibroblasts." *Free Radical Biology and Medicine* no. 165:282-288. doi: <https://doi.org/10.1016/j.freeradbiomed.2021.01.032>.
- McKenzie, Matthew, Danae Liolitsa, Natalya Akinshina, Michelangelo Campanella, Sanjay Sisodiya, Ian Hargreaves, Niranjanan Nirmalanathan, Mary G. Sweeney, Patrick M. Abou-Sleiman, Nicholas W. Wood, Michael G. Hanna, and Michael R. Duchen. 2007. "Mitochondrial *ND5* Gene Variation Associated with Encephalomyopathy and Mitochondrial ATP Consumption." *Journal of Biological Chemistry* no. 282 (51):36845-36852. doi: 10.1074/jbc.M704158200.
- Moosmann, Bernd, and Christian Behl. 2004. "Selenoproteins, cholesterol-lowering drugs, and the consequences revisiting of the mevalonate pathway." *Trends in Cardiovascular Medicine* no. 14 (7):273-281.
- Mugoni, V., R. Postel, V. Catanzaro, E. De Luca, E. Turco, G. Digilio, L. Silengo, M. P. Murphy, C. Medana, D. Y. Stainier, J. Bakkers, and M. M. Santoro. 2013. "Ubiad1 is an antioxidant enzyme that regulates eNOS activity by CoQ10 synthesis." *Cell* no. 152 (3):504-18. doi: 10.1016/j.cell.2013.01.013.
- Ognjanović, Branka I, Snežana D Marković, Nataša Z Đorđević, Ivana S Trbojević, Andraš Š Štajn, and Zorica S Saičić. 2010. "Cadmium-induced lipid peroxidation and changes in antioxidant defense system in the rat testes: Protective role of coenzyme Q10 and Vitamin E." *Reproductive Toxicology* no. 29 (2):191-197.
- Ognjanović, Branka I, Snezana D Marković, Slađan Z Pavlović, Radoslav V Žikić, and AŠ Štajn. 2008. "Effect of chronic cadmium exposure on antioxidant defense system in some tissues of rats: protective effect of selenium." *Physiological research* no. 57 (3).
- Okamura, Takao, Makoto Sunamori, Jun Amano, Yasumasa Hirooka, Masayoshi Ozeki, Atushi Tanaka, and Akio Suzuki. 1984. "Combined treatment of coenzyme Q10 and aprotinin with intraaortic balloon pumping following aorto-coronary bypass surgery." *The Japanese journal of surgery* no. 14 (2):97-103. doi: 10.1007/BF02469798.

- Okuyama, H., P. H. Langsjoen, T. Hamazaki, Y. Ogushi, R. Hama, T. Kobayashi, and H. Uchino. 2015. "Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms." *Expert Rev Clin Pharmacol* no. 8 (2):189-99. doi: 10.1586/17512433.2015.1011125.
- Perumal, S. S., P. Shanthi, and P. Sachdanandam. 2005a. "Augmented efficacy of tamoxifen in rat breast tumorigenesis when gavaged along with riboflavin, niacin, and CoQ10: effects on lipid peroxidation and antioxidants in mitochondria." *Chem Biol Interact* no. 152 (1):49-58. doi: 10.1016/j.cbi.2005.01.007.
- Perumal, S. S., P. Shanthi, and P. Sachdanandam. 2005b. "Energy-modulating vitamins--a new combinatorial therapy prevents cancer cachexia in rat mammary carcinoma." *Br J Nutr* no. 93 (6):901-9. doi: 10.1079/bjn20051439.
- Perumal, Selvanathan Saravana, Palanivelu Shanthi, and Panchanadham Sachdanandam. 2005c. "Augmented efficacy of tamoxifen in rat breast tumorigenesis when gavaged along with riboflavin, niacin, and CoQ10: Effects on lipid peroxidation and antioxidants in mitochondria." *Chemico-Biological Interactions* no. 152 (1):49-58. doi: <https://doi.org/10.1016/j.cbi.2005.01.007>.
- Podda, Maurizio, Maret G Traber, Christine Weber, Liang-Jun Yan, and Lester Packer. 1998. "UV-irradiation depletes antioxidants and causes oxidative damage in a model of human skin." *Free Radical Biology and Medicine* no. 24 (1):55-65.
- Poot, Martin, Anton Verkerk, Johan F Koster, Hermann Esterbauer, and Johan F Jongkind. 1987. "Influence of cumene hydroperoxide and 4-hydroxynonenal on the glutathione metabolism during in vitro ageing of human skin fibroblasts." *European journal of Biochemistry* no. 162 (2):287-291.
- Prakash, S., J. Sunitha, and M. Hans. 2010. "Role of coenzyme Q(10) as an antioxidant and bioenergizer in periodontal diseases." *Indian J Pharmacol* no. 42 (6):334-7. doi: 10.4103/0253-7613.71884.
- Premkumar, V. G., S. Yuvaraj, K. Vijayasarathy, S. G. Gangadaran, and P. Sachdanandam. 2007a. "Effect of coenzyme Q10, riboflavin and niacin on serum CEA and CA 15-3 levels in breast cancer patients undergoing tamoxifen therapy." *Biol Pharm Bull* no. 30 (2):367-70. doi: 10.1248/bpb.30.367.
- Premkumar, V. G., S. Yuvaraj, K. Vijayasarathy, S. G. Gangadaran, and P. Sachdanandam. 2007b. "Serum cytokine levels of interleukin-1beta, -6, -8, tumour necrosis factor-alpha and vascular endothelial growth factor in breast cancer patients treated with tamoxifen and supplemented with co-enzyme Q(10), riboflavin and niacin." *Basic Clin Pharmacol Toxicol* no. 100 (6):387-91. doi: 10.1111/j.1742-7843.2007.00065.x.
- Premkumar, Vummidi Giridhar, Srinivasan Yuvaraj, Palanivel Shanthi, and Panchanatham Sachdanandam. 2008. "Co-enzyme Q10, riboflavin and niacin supplementation on alteration of DNA repair enzyme and DNA

- methylation in breast cancer patients undergoing tamoxifen therapy." *British Journal of Nutrition* no. 100 (6):1179-1182. doi: 10.1017/S0007114508968276.
- Qi, X., Z. Wan, B. Jiang, Y. Ouyang, W. Feng, H. Zhu, Y. Tan, R. He, L. Xie, and Y. Li. 2022. "Inducing ferroptosis has the potential to overcome therapy resistance in breast cancer." *Front Immunol* no. 13:1038225. doi: 10.3389/fimmu.2022.1038225.
- Rosenfeldt, Erik J, and Karl G Linden. 2007. "The R OH, UV concept to characterize and the model UV/H₂O₂ process in natural waters." *Environmental science & technology* no. 41 (7):2548-2553.
- Ryo, K., A. Ito, R. Takatori, Y. Tai, K. Arikawa, T. Seido, T. Yamada, K. Shinpo, Y. Tamaki, K. Fujii, Y. Yamamoto, and I. Saito. 2011. "Effects of coenzyme Q10 on salivary secretion." *Clin Biochem* no. 44 (8-9):669-74. doi: 10.1016/j.clinbiochem.2011.03.029.
- Seet, Raymond Chee-Seong, Erle CH Lim, June JH Tan, Amy ML Quek, Adeline WL Chow, Wan-Ling Chong, Mary PE Ng, Choon-Nam Ong, and Barry Halliwell. 2014. Does high-dose coenzyme Q10 improve oxidative damage and clinical outcomes in Parkinson's disease? : Mary Ann Liebert, Inc. 140 Huguenot Street, 3rd Floor New Rochelle, NY 10801 USA.
- Shetty, R. A., M. J. Forster, and N. Sumien. 2013. "Coenzyme Q(10) supplementation reverses age-related impairments in spatial learning and lowers protein oxidation." *Age (Dordr)* no. 35 (5):1821-34. doi: 10.1007/s11357-012-9484-9.
- Shimizu, Megumi, Tetsuro Miyazaki, Atsutoshi Takagi, Yurina Sugita, Shoichiro Yatsu, Azusa Murata, Takao Kato, Shoko Suda, Shohei Ouchi, and Tatsuro Aikawa. 2017. "Low circulating coenzyme Q10 during acute phase is associated with inflammation, malnutrition, and in-hospital mortality in patients admitted to the coronary care unit." *Heart and vessels* no. 32:668-673.
- Shindo, Yasuko, Eric Witt, Derick Han, and Lester Packer. 1994. "Dose-response effects of acute ultraviolet irradiation on antioxidants and molecular markers of oxidation in murine epidermis and dermis." *Journal of Investigative Dermatology* no. 102 (4):470-475.
- Shukla, S., and K. K. Dubey. 2018. "CoQ10 a super-vitamin: review on application and biosynthesis." *3 Biotech* no. 8 (5):249. doi: 10.1007/s13205-018-1271-6.
- Somayajulu, Mallika, S McCarthy, M Hung, M Sikorska, H Borowy-Borowski, and S Pandey. 2005. "Role of mitochondria in neuronal cell death induced by oxidative stress; neuroprotection by Coenzyme Q10." *Neurobiology of disease* no. 18 (3):618-627.
- Song, Min-Hae, Ha-Na Kim, Yong Lim, and In-Surk Jang. 2017. "Effects of coenzyme Q 10 on the antioxidant system in SD rats exposed to lipopolysaccharide-induced toxicity." *Laboratory animal research* no. 33:24-31.
- Spindler, Meredith, M Flint Beal, and Claire Henchcliffe. 2009. "Coenzyme Q10

- effects in neurodegenerative disease." *Neuropsychiatric disease and treatment*:597-610.
- Sreedhar, Annapoorna, Leopoldo Aguilera-Aguirre, and Keshav K. Singh. 2020. "Mitochondria in skin health, aging, and disease." *Cell Death & Disease* no. 11 (6):444. doi: 10.1038/s41419-020-2649-z.
- Temova Rakuša, Žane, and Robert Roškar. 2021. "Quality Control of Vitamins A and E and Coenzyme Q10 in Commercial Anti-Ageing Cosmetic Products." *Cosmetics* no. 8 (3):61.
- Tippairote, T., G. Bjørklund, A. Gasmi, Y. Semenova, M. Peana, S. Chirumbolo, and T. Hangan. 2022. "Combined Supplementation of Coenzyme Q(10) and Other Nutrients in Specific Medical Conditions." *Nutrients* no. 14 (20). doi: 10.3390/nu14204383.
- Tomofuji, T., T. Azuma, H. Kusano, T. Sanbe, D. Ekuni, N. Tamaki, T. Yamamoto, and T. Watanabe. 2006. "Oxidative damage of periodontal tissue in the rat periodontitis model: effects of a high-cholesterol diet." *FEBS Lett* no. 580 (15):3601-4. doi: 10.1016/j.febslet.2006.05.041.
- Tsubaki, K., A. Horiuchi, T. Kitani, N. Taniguchi, T. Masaoka, H. Shibata, T. Yonezawa, T. Tsubakio, H. Kawagoe, Y. Shinohara, and et al. 1984. "[Investigation of the preventive effect of CoQ10 against the side-effects of anthracycline antineoplastic agents]." *Gan To Kagaku Ryoho* no. 11 (7):1420-7.
- Varela-López, A., F. Giampieri, M. Battino, and J. L. Quiles. 2016. "Coenzyme Q and Its Role in the Dietary Therapy against Aging." *Molecules* no. 21 (3):373. doi: 10.3390/molecules21030373.
- von Kleist-Retzow, Jürgen-Christoph, Hue-Tran Hornig-Do, Matthias Schauen, Sabrina Eckertz, Tuan Anh Duong Dinh, Frank Stassen, Nadine Lottmann, Maria Bust, Bistra Galunska, and Klaus Wielckens. 2007. "Impaired mitochondrial Ca²⁺ homeostasis in respiratory chain-deficient cells but efficient compensation of energetic disadvantage by enhanced anaerobic glycolysis due to low ATP steady state levels." *Experimental cell research* no. 313 (14):3076-3089.
- Yoneda, T., T. Tomofuji, D. Ekuni, T. Azuma, Y. Endo, K. Kasuyama, T. Machida, and M. Morita. 2013. "Anti-aging effects of co-enzyme Q10 on periodontal tissues." *J Dent Res* no. 92 (8):735-9. doi: 10.1177/0022034513490959.
- Yuvaraj, S., V. G. Premkumar, P. Shanthi, K. Vijayasathy, S. G. Gangadaran, and P. Sachdanandam. 2009. "Effect of Coenzyme Q(10), Riboflavin and Niacin on Tamoxifen treated postmenopausal breast cancer women with special reference to blood chemistry profiles." *Breast Cancer Res Treat* no. 114 (2):377-84. doi: 10.1007/s10549-008-0012-7.
- Yuvaraj, S., V. G. Premkumar, K. Vijayasathy, S. G. Gangadaran, and P. Sachdanandam. 2007. "Ameliorating effect of coenzyme Q10, riboflavin and niacin in tamoxifen-treated postmenopausal breast cancer patients with special reference to lipids and lipoproteins." *Clin Biochem* no. 40 (9-10):623-8. doi: 10.1016/j.clinbiochem.2007.02.003.

Zhong, Liangwei, and Arne Holmgren. 2000. "Essential Role of Selenium in the Catalytic Activities of Mammalian Thioredoxin Reductase Revealed by Characterization of Recombinant Enzymes with Selenocysteine Mutations*." *Journal of Biological Chemistry* no. 275 (24):18121-18128. doi: <https://doi.org/10.1074/jbc.M000690200>.

Zwerschke, Werner, Sybille Mazurek, Petra Stöckl, Eveline Hütter, Erich Eigenbrodt, and Pidder Jansen-Dürr. 2003. "Metabolic analysis of senescent human fibroblasts reveals a role for AMP in cellular senescence." *Biochemical journal* no. 376 (2):403-411.